R W Shafer
Overview
Explore the profile of R W Shafer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
1356
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zazzi M, Kaiser R, Sonnerborg A, Struck D, Altmann A, Prosperi M, et al.
HIV Med
. 2010 Aug;
12(4):211-8.
PMID: 20731728
Objectives: The EuResist expert system is a novel data-driven online system for computing the probability of 8-week success for any given pair of HIV-1 genotype and combination antiretroviral therapy regimen...
2.
Kapoor A, Victoria J, Simmonds P, Wang C, Shafer R, Nims R, et al.
J Virol
. 2007 Oct;
82(1):311-20.
PMID: 17942560
Nucleic acids from an unidentified virus from ringed seals (Phoca hispida) were amplified using sequence-independent PCR, subcloned, and then sequenced. The full genome of a novel RNA virus was derived,...
3.
Canter J, Haas D, Kallianpur A, Ritchie M, Robbins G, Shafer R, et al.
Pharmacogenomics J
. 2007 Aug;
8(1):71-7.
PMID: 17684475
Peripheral neuropathy (PN) due to mitochondrial injury complicates HIV therapy with some nucleoside reverse transcriptase inhibitors (NRTIs). Variation in the mitochondrial genome may influence susceptibility to NRTI toxicities. Two non-synonymous...
4.
Deforche K, Camacho R, Grossman Z, Silander T, Soares M, Moreau Y, et al.
Infect Genet Evol
. 2006 Nov;
7(3):382-90.
PMID: 17127103
Interpretation of Human Immunodeficiency Virus 1 (HIV-1) genotypic drug resistance is still a major challenge in the follow-up of antiviral therapy in infected patients. Because of the high degree of...
5.
Kapoor A, Jones M, Shafer R, Rhee S, Kazanjian P, Delwart E
J Virol
. 2004 Jun;
78(13):7112-23.
PMID: 15194787
Drug-resistant viruses may be present as minority variants during early treatment failures or following discontinuation of failed antiretroviral regimens. A limitation of the traditional direct PCR population sequencing method is...
6.
Shafer R, Kroodsma K
Drugs Today (Barc)
. 2004 Feb;
34(8):663-72.
PMID: 14988773
Major recent advances in HIV diagnosis include rapid screening serological tests that yield results on the same day of testing, new serological tests that detect infection with a wide variety...
7.
GONZALES M, Machekano R, Shafer R
J Infect Dis
. 2001 Sep;
184(8):998-1006.
PMID: 11574914
Phylogenetic analysis of the reverse transcriptase (RT) and protease of 117 published complete human immunodeficiency virus (HIV) type 1 genome sequences demonstrated that these genes cluster into distinct subtypes. There...
8.
Shulman N, Machekano R, Shafer R, Winters M, Zolopa A, Liou S, et al.
J Acquir Immune Defic Syndr
. 2001 Jul;
27(4):377-80.
PMID: 11468426
Prior evidence suggests that resistance to zidovudine (ZDV) confers some degree of cross-resistance to stavudine (d4T), but no genotypic correlates of clinical d4T susceptibility and resistance exist. To identify the...
9.
Shulman N, Zolopa A, Passaro D, Shafer R, Huang W, Katzenstein D, et al.
AIDS
. 2001 Jun;
15(9):1125-32.
PMID: 11416714
Background: Enhanced susceptibility to non-nucleoside reverse transcriptase inhibitors (NNRTI) was recently described in association with increased resistance to nucleoside analogs (nucleoside reverse transcriptase inhibitors; NRTI). Objectives: To determine the prevalence...
10.
Smeaton L, Degruttola V, Robbins G, Shafer R
Control Clin Trials
. 2001 Apr;
22(2):142-59.
PMID: 11306153
ACTG (AIDS Clinical Trials Group) 384 is designed to evaluate different strategies for antiretroviral treatment in HIV-1-infected individuals with no previous exposure to antiretroviral treatment. The study is a randomized,...